PL
JAZZ icon

Parkwood LLC’s Jazz Pharmaceuticals JAZZ Stock Holding History

Parkwood LLC’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-1,446
Closed -$255K – 522
2015
Q2 		$255K Buy
+1,446
New +$260K 0.04% 438

Other funds holding JAZZ

PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
WBC
Westpac Banking Corp Sydney, Australia $1.44B AUM 28.5% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Parkwood LLC's JAZZ Position: Q3 2015 in Review

Parkwood LLC sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2015, closing a stake of 1,446 shares — an estimated $255K sold.

Parkwood LLC first reported a position in JAZZ in Q2 2015 and held it in 1 quarter. The position peaked at $255K in Q2 2015. 360 funds tracked by Wall St. Rank hold JAZZ as of Q3 2015.

  • Parkwood LLC reported no remaining Jazz Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Parkwood LLC sold 1,446 Jazz Pharmaceuticals shares in Q3 2015, an estimated $255K.
  • Parkwood LLC first reported a position in Jazz Pharmaceuticals in Q2 2015 and held it in 1 quarter.
  • Parkwood LLC's Jazz Pharmaceuticals position peaked at $255K in Q2 2015.
  • 360 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2015.

Based on Parkwood LLC's 13F filing for Q3 2015, filed 23 Oct 2015.